David Turveson (Cold Spring Harbor NY) #AACR23 A road map to defeat pancreatic cancer.

7:05am April 18th 2023 via Twitter Web App

Hudson #AACR23 Barriers to integration: knowledge or skills; communication from oncologist to PCP, EMRs variable, c… https://t.co/0RPorsXIl3

3:50pm April 17th 2023 via Twitter Web App

Hudson #AACR23 Psychosocial issues - one is financial hardship by families. 22% material hardship, 30% coping/behav… https://t.co/MgnKYgaMvb

3:45pm April 17th 2023 via Twitter Web App

Hudson #AACR23 Shows increasing adherence to recommended survivorship care, from 20% to about 40% now. Even though… https://t.co/6LOtrtmjHe

3:43pm April 17th 2023 via Twitter Web App

Hudson #AACR23 Updated cardiomyopathy recommendations for surveillance. '23 ref https://t.co/ismGZwBHJR

3:39pm April 17th 2023 via Twitter Web App

Hudson #AACR23 Second exemplar - anthracylin-related cardiotoxicity. Cardiac events and congestive heart failure in… https://t.co/YFxeX6tUWA

3:37pm April 17th 2023 via Twitter Web App

Hudson #AACR23 Recommend now for BC pediatric survivors, yearly mammogram (beginning 8y after radiation or age 25 w… https://t.co/wBfi1GpLCq

3:35pm April 17th 2023 via Twitter Web App

Hudson #AACR23 After anthracyclines - 13x hazard ratio at the highest dosage; 15% risk of breast cancer at 50yo. Sh… https://t.co/QdoJl1LKxN

3:33pm April 17th 2023 via Twitter Web App

Hudson #AACR23 In breast cancer - cumulative incidence 13% - 20% by age 40-45y. As high as 35% by age 50. https://t.co/olnKb5w2cp

3:29pm April 17th 2023 via Twitter Web App

Hudson #AACR23 Two exemplars to illustrate how high-risk groups have clinical risk prediction models and dev of int… https://t.co/7EBfnDsB74

3:27pm April 17th 2023 via Twitter Web App

Hudson #AACR23 With data, worked with IOM for guidelines to publish the first version in 2003, now on it's 5th edit… https://t.co/ugNTTrcIm4

3:25pm April 17th 2023 via Twitter Web App

Hudson #AACR23 After tracking for 50y, can relate Rx to late effects. Expanded now to genetic factors (BRCA, ATM, p… https://t.co/JvlXv09jP8

3:22pm April 17th 2023 via Twitter Web App

Hudson #AACR23 Survivors by age 40 - 50 with at least one life-threatening condition. Shows a detailed, cumulative… https://t.co/uMbgIgXZf9

3:16pm April 17th 2023 via Twitter Web App

Hudson #AACR23 still plenty of life-altering late-effects; infertility, seizures, neurocognitive deficits, hearing/… https://t.co/jsadbE8LEE

3:13pm April 17th 2023 via Twitter Web App

Hudson #AACR23 Late effects as a stimulus for change - now risk stratification of front-line cancer therapy, reduci… https://t.co/FM7wMY4VLU

3:12pm April 17th 2023 via Twitter Web App

Hudson #AACR23 Shows SEER data w/5y survival increasing: due to collab trials, understanding cancer pathobiology...… https://t.co/xgLFvvRHww

3:09pm April 17th 2023 via Twitter Web App

Melissa Hudson (St Jude Children's Res Hosp Memphis TN) #AACR23 AACR-Joseph Burchenal Award for outstanding achieve… https://t.co/dfvRIdvAxd

3:08pm April 17th 2023 via Twitter Web App

Fertig #AACR23 '16 Review - illustrating important points about sc analyses https://t.co/Lg50Ygkqak Finding domina… https://t.co/6SrYFhf1v5

8:57am April 17th 2023 via Twitter Web App

Fertig #AACR23 Review of Panc cancer - https://t.co/bcFtsse5ft Spatial proteomics maps immunosuppressive cells such… https://t.co/IzYga7YL75

8:54am April 17th 2023 via Twitter Web App

Fertig #AACR23 She comes from weather forecasting using math models. '21 ref https://t.co/70mUuWXyga

8:52am April 17th 2023 via Twitter Web App

Elana Fertig (Johns Hopkins MD USA) #AACR23 Forecasting pancreatic carcinogenesis through spatial multiomics. High-… https://t.co/MJj17tNElv

8:51am April 17th 2023 via Twitter Web App

Hwang #AACR23 Last section - technological advances to allow earlier detection. 37T cells in the body; 1T seconds =… https://t.co/gwWPKTACHo

8:44am April 17th 2023 via Twitter Web App

Hwang #AACR23 able to stain via MIBI-TOF 37-marker panel, from DCIS, Risom et al Cell 2021 https://t.co/7hpc5nXQ7i… https://t.co/OhiF9PMnHe

8:39am April 17th 2023 via Twitter Web App

Hwang #AACR23 Trends in incidence rates from SEER - incidence is flat - but is costly, ~$5B annually. But 'if it we… https://t.co/vf9HpFIx3t

8:35am April 17th 2023 via Twitter Web App

Hwang #AACR23 For prostate, thyroid, breast cancer: lifetime risk is 4%, 0.1%, 4% respectively. But the disease res… https://t.co/PGQMRFDiT3

8:32am April 17th 2023 via Twitter Web App

Hwang #AACR23 Stance was to be always treat it; natural history unknown. Defines overdiagnosis: 'of a disease that… https://t.co/LVEOVqhCUF

8:30am April 17th 2023 via Twitter Web App

Shelley Hwang (Duke Univ NC) #AACR23 When to intervene along the breast cancer continuum? Starts with DCIS - ducta… https://t.co/4yxPptnG7E

8:29am April 17th 2023 via Twitter Web App

Malkin #AACR23 For germline can look at somatic p53 mutations, CNV, methylation, fragmentome, etc from cfDNA in LFS… https://t.co/LhtvuFYVAC

7:36am April 17th 2023 via Twitter Web App

Malkin #AACR23 cfDNA analysis can be tailored to detect different t ypes of genome variation; "all are needed for h… https://t.co/wKobjlYo9m

7:34am April 17th 2023 via Twitter Web App

Malkin #AACR23 Pre-cancer event - in sporadic cancers - but this happens early, perhaps not that long 'after concep… https://t.co/lmPFwXY5ac

7:31am April 17th 2023 via Twitter Web App

Malkin #AACR23 1/2 show chromothripsis. Looked for a pattern of SNVs - had variants in one of the DNA pathway repai… https://t.co/RWPREIZejR

7:31am April 17th 2023 via Twitter Web App

Malkin #AACR23 Found molecular signatures in Li-Fraumeni syndrome tumors; an aging signature found in all tumors; s… https://t.co/E8OHVE869M

7:28am April 17th 2023 via Twitter Web App

Malkin #AACR23 Can we learn something from the somatic genome? Li-Fraumeni Syndrome genome landscape, WGS analysis… https://t.co/kcrTUFGBZT

7:26am April 17th 2023 via Twitter Web App

Malkin #AACR23 Dx of pre-B ALL (masked hypodiploid), 5% MRD after induction (high risk protocol, bad news). After m… https://t.co/ch6Q835Neu

7:25am April 17th 2023 via Twitter Web App

Malkin #AACR23 p53 surveillance, around the world. Shows a 15yo female who was diagnosed pre-natal. Shows 'pre-symp… https://t.co/MDZrkjoE13

7:23am April 17th 2023 via Twitter Web App

Malkin #AACR23 There is a large Int'l replication repair deficiency consortia. Last example: Li-Fraumeni syndrome p… https://t.co/2hYWLqeBIU

7:21am April 17th 2023 via Twitter Web App

Malkin #AACR23 Shows OS data from this 2022 ref, with additional evidence (survival) in GBM; have to know the under… https://t.co/PJgQC4wOy4

7:20am April 17th 2023 via Twitter Web App

Malkin #AACR23 CMMRD tumors are 'attractive targets for ICI's' showing mutation burden across 7K cancers, dramatic… https://t.co/olByKGvAPh

7:18am April 17th 2023 via Twitter Web App

Malkin #AACR23 Outlines info about CMMRD from this ref https://t.co/P4AQyuwTov

7:16am April 17th 2023 via Twitter Web App

Malkin #AACR23 Shows the shift in fragment length in cancers. Shift to topic 2: mis-match repair syndrome. 5yo girl… https://t.co/b5xgIRKOsd

7:15am April 17th 2023 via Twitter Web App

Malkin #AACR23 For MPNST (pre-malignant disease), how do you rule it out? cfDNA 150-350bp fragments consistent with… https://t.co/EdpGn4Mtvr

7:12am April 17th 2023 via Twitter Web App

Malkin #AACR23 Results of Ph II trials of Sunitinib in children with PN: approved in CAN, showed 26/50 (56%) durabl… https://t.co/qmjclP4tlL

7:11am April 17th 2023 via Twitter Web App

Malkin #AACR23 Treatment targets in NF1: Farnesyltransferase inh; RTKi / Angiogenesis / TME; mTOR inh; MEK inh. "As… https://t.co/YBnQkv9dBp

7:09am April 17th 2023 via Twitter Web App

Malkin #AACR23 Shows malignant progression assoc'd with genetic evolution; accumulation events, biallelic loss of N… https://t.co/XPNR0XGOlD

7:08am April 17th 2023 via Twitter Web App

Malkin #AACR23 One of three context: Neurofibromatosis Type 1 (NF 1), 1:3500 freq single-gene disorder. Tumor dev,… https://t.co/RpvIsh4zhD

7:07am April 17th 2023 via Twitter Web App

Malkin #AACR23 Most findinds are new information; 78%, 22% previously known. Medulloblastoma - clinical outcome ass… https://t.co/FXbc5fYRNl

7:05am April 17th 2023 via Twitter Web App

Malkin #AACR23 Pediatric world is ahead of the adult oncology one: germline variants are common. Nature Cancer 2022… https://t.co/fGm4ZOzSaW

7:04am April 17th 2023 via Twitter Web App

Good morning! David Malkin (Univ Toronto CAN) #AACR23 Prediction and prevention: seeking the holy grail for cancer… https://t.co/IOJ9kQmIFh

7:02am April 17th 2023 via Twitter Web App

June #AACR23 CD2 CAR-T cell therapy have acceptable toxicity and efficacy in pediatric solid tumors.… https://t.co/kr3ZCZewNm

5:08pm April 16th 2023 via Twitter Web App

June #AACR23 With Human T-cells, many genes to knock out - shows a list of 30 genes, to address many issues in soli… https://t.co/NqFP6qodzs

5:06pm April 16th 2023 via Twitter Web App